Introduction
============

Lung cancer has a substantial mortality rate and the incidence of lung cancer has been increasing gradually ([@b1-ol-0-0-8105]--[@b5-ol-0-0-8105]). Based on histological type, lung cancer may be divided into two categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). From all types of lung cancer, 80--85% are classified as NSCLC ([@b6-ol-0-0-8105],[@b7-ol-0-0-8105]). Additionally, in \>70% of newly diagnosed NSCLC cases, the disease is at an advanced stage, and the 5-year survival rate of patients with NSCLC is only 16% ([@b8-ol-0-0-8105]). Hence, it is imperative to identify potential molecular mechanisms of NSCLC tumorigenesis and progression.

Non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) and microRNAs (miRNA/miR), have been demonstrated to function differently in different types of cancer. Different ncRNAs in the same cancer may have different underlying functions ([@b9-ol-0-0-8105],[@b10-ol-0-0-8105]). Previous studies demonstrated that ncRNAs are extensively involved in the tumorigenesis and progression of NSCLC ([@b11-ol-0-0-8105],[@b12-ol-0-0-8105]). Various lncRNAs have been confirmed to have significant functions in epigenetic gene regulation, transcriptional regulation or disease development ([@b13-ol-0-0-8105]--[@b16-ol-0-0-8105]). It is of note that lncRNAs may regulate the transcription of corresponding genes by combining with polymerases or transcription factors due to their pervasive distribution in the nucleus ([@b15-ol-0-0-8105],[@b17-ol-0-0-8105]). Previous studies have revealed that lncRNAs may regulate miRNA expression in lung cancer. With regards to the interplay between lncRNAs and miRNAs during tumorigenesis and progression, the competing endogenous RNA (ceRNA) hypothesis has attracted attention ([@b18-ol-0-0-8105],[@b19-ol-0-0-8105]). The ceRNA hypothesis posits that lncRNAs function as molecular sponges for miRNAs and functionally liberate the targeted mRNAs regulated by the aforementioned miRNAs ([@b20-ol-0-0-8105]--[@b22-ol-0-0-8105]). For example, the lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) may function as a ceRNA for miR-377-3p, and NEAT1 promotes NSCLC progression by regulating the expression of miR-377-3p ([@b23-ol-0-0-8105]). The lncRNA colon cancer-associated transcript 1 (non-protein coding) reduced miR-218 levels via the use of BMI1 proto-oncogene, polycomb ring finger to promote cell cycle transition in cigarette smoke extract-induced lung carcinogenesis ([@b24-ol-0-0-8105]). The lncRNA urothelial cancer associated one performed oncogenic functions in NSCLC by targeting miR-193a-3p ([@b25-ol-0-0-8105]). Furthermore, lncRNAs may co-express with microRNA in diseases. For example, Keniry *et al* ([@b26-ol-0-0-8105]) revealed that lncRNA H19, imprinted maternally expressed transcript (non-protein coding) may function as the pre-miRNA of miR-675, and they may interplay to suppress growth. Furthermore, miRNAs regulate the expression of their target transcripts by binding to the 3′-untranslated region (3′-UTR) ([@b27-ol-0-0-8105]--[@b32-ol-0-0-8105]). For example, Huang *et al* ([@b33-ol-0-0-8105]) revealed that miRNA-186 may suppress the cell proliferation and metastasis of NSCLC by targeting mitogen-activated protein kinase kinase kinase 2. Lu *et al* ([@b34-ol-0-0-8105]) revealed that miR-541-3p may reverse cancer progression by directly targeting TGFB induced factor homeobox 2 in NSCLC. Hence, the further investigation of miRNA profiling associated with lncRNAs in NSCLC is useful in order to identify novel targeted therapeutic strategies.

In the present study, a microarray analysis was performed to verify the differential expression of miRNAs between the RNA interference (RNAi) and control samples according to the fold change filtering (fold change ≥1.5 or ≤1) and the P-value (P\<0.05). The five most downregulated miRNAs were selected (miR-1264, miR-337-3p, miR-302c-5p, miR-642b-3p and miR-3621). Then, based on original data from The Cancer Genome Atlas (TCGA), miR-642b-3p was selected for further analysis. Four miRNA target prediction algorithms were used to identify the potential target genes of miR-642b-3p. Bioinformatics analysis, including Gene Ontology (GO), the Kyoto Encyclopaedia of Genes and Genomes (KEGG), protein-protein interactions (PPIs) and network analysis were performed in order to investigate the potential functions, pathways and networks of the target genes ([@b35-ol-0-0-8105]--[@b38-ol-0-0-8105]). Additionally, the expression of miR-642b-3p and its targeted genes \[zinc finger protein 350 (ZNF350), heterogeneous nuclear ribonucleoprotein U (HNRNPU), high mobility group box 1 (HMGB1), phosphodiesterase 4D (PDE4D), synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP), basic helix-loop-helix family member B9 (BHLHB9)\] in NSCLC was analysed based on original data from TCGA database.

Materials and methods
=====================

### Microarray analysis and the knockdown of HOXA11 antisense RNA (HOXA11-AS) in the NSCLC cell line A549

The A549 human NSCLC cell line was purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China), and cultivated in a humidified atmosphere of 5% CO~2~ at 37°C with 10% heat-inactivated foetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The A549 NSCLC cell line was transfected with HOXA11-AS small interfering RNA and the subsequent experiments were performed at least 72 h following transfection. Lipofectamine™ 2000 (cat no. 11668-019; Invitrogen; Thermo Fisher Scientific, Inc.) was used for transfection, according to the manufacturer\'s protocol. A microarray analysis was performed in order to verify the differential expression of miR-642b-3p between the RNAi and control samples according to fold-change filtering (fold-change ≥1.5 or ≤1) and P-value (P\<0.05).

### miRNA target prediction

Four miRNA target prediction algorithms were utilized to predict the potential target genes of miR-642b-3p. The four corresponding prediction algorithms were miRDB (version 4.0, <http://www.mirdb.org/>) ([@b39-ol-0-0-8105],[@b40-ol-0-0-8105]), mirTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>) ([@b41-ol-0-0-8105]), TargetScan (version 6.2; <http://www.targetscan.org/>) ([@b42-ol-0-0-8105]) and DIANA-microT (version v4.0; <http://www.microrna.gr/microT>) ([@b43-ol-0-0-8105],[@b44-ol-0-0-8105]). Candidate genes were identified and compared with Venn diagrams (<http://bioinformatics.psb.ugent.be/webtools/Venn/>).

### GO and pathway analysis and construction of a PPI network

To elucidate the potential functions of the target genes, GO and KEGG pathway analyses were conducted at the biological process (BP), cellular component (CC) and molecular function (MF) levels, as previously described ([@b45-ol-0-0-8105]). The enrichment of potential target genes was further analysed using the Database for Annotation, Visualization and Integrated Discovery (DAVID, version 6.7, <http://david.abcc.ncifcrf.gov/>) ([@b46-ol-0-0-8105],[@b47-ol-0-0-8105]) or Search Tool for the Retrieval of Interacting Genes (STRING; version 9.0; <http://string-db.org>) ([@b48-ol-0-0-8105]). Genes with a false discovery rate of ≤0.05 and P\<0.05 were identified as enriched in the target genes. Then, a functional network of GO analysis was constructed using Cytoscape (version 2.8; <http://cytoscape.org>) ([@b49-ol-0-0-8105]).

The interaction pairs of target genes were additionally analysed using STRING version 9.0, and the interaction data was downloaded and analysed as described ([@b50-ol-0-0-8105]). A combined score \>0.4 was selected as a threshold in order to construct the PPI network.

### Additional analysis of miR-642b-3p and target genes in NSCLC from TCGA

TCGA (<http://cancergenome.nih.gov/>) is a collection of RNA sequencing, miRNA sequencing, exome sequencing, single nucleotide polymorphism array and DNA methylation data ([@b51-ol-0-0-8105]). TCGA may also be used to analyse clinical parameters and complicated cancer genomics ([@b52-ol-0-0-8105],[@b53-ol-0-0-8105]). In the present study, raw data from RNASeq version 2 ([@b54-ol-0-0-8105],[@b55-ol-0-0-8105]) in lung adenocarcinoma and squamous cell carcinoma for miR-642b and the 6 target genes (ZNF350, HNRNPU, HMGB1, PDE4D, SYNCRIP and BHLHB9) were extracted from TCGA. The expression of miR-642b and the target genes in each case was subsequently calculated according to the distribution of exon reads.

### Statistical analysis

SPSS version 20.0 (IBM Corporation, Armonk, NY, USA) was used for statistical analysis. An unpaired Student\'s t-test was used for comparing the expression of miR-642b-3p and its target genes in lung adenocarcinoma and squamous cell carcinoma. The association between HOXA11-AS, miR-642b-3p and target genes were evaluated using Spearman\'s test. The association between gene expression and clinical diagnostic values was analysed using receiver operating characteristic curves. A Kaplan-Meier survival analysis was used to produce survival curves. P\<0.05 was considered to indicate a statistically significant difference (two-tailed).

Results
=======

### miR-642b-3p profiling was associated with lncRNA HOXA11-AS

The transfection efficiency was \~100%, and the knockdown efficiency of HOXA11-AS in NSCLC cell lines was \>75%, as determined by a reverse transcription-quantitative polymerase chain reaction (RT-qPCR; data not presented). Following the knockdown of HOXA11-AS, miR-642b-3p was significantly downregulated in A549 NSCLC cells (fold-change=0.355 and P=0.008).

### miRNA target prediction

In the present study, four miRNA target prediction algorithms (miRDB, mirTarBase, TargetScan and DIANA-microT) were used to identify the target genes of miR-642b-3p. Venn diagrams were generated in order to analyse and compare the candidate genes. Amongst these target genes, 705 genes (including ZNF350, MAPK8, ASTN2 and YOD1) that were predicted by \>2 algorithms were selected and these genes were used for GO and pathway analyses.

### GO and pathway analysis and construction of a PPI network

The GO analysis was performed at the BP, CC and MF levels. The top 5 GO functional annotations for the target genes of miR-642b are presented in [Table I](#tI-ol-0-0-8105){ref-type="table"}. GO analysis indicated the significant functional groups, including multicellular organism development, intracellular part and molecular function. To further elucidate the relevant functions of the target genes, a functional network was constructed based on the GO analysis using Cytoscape ([Fig. 1](#f1-ol-0-0-8105){ref-type="fig"}).

Using the online tools DAVID or STRING, the KEGG analysis demonstrated that the target genes may be involved in different pathways, including the avian erythroblastosis oncogene B2 signalling pathway, RIG-I-like receptor signalling pathway or mitogen-activated protein kinases (MAPK) signalling pathway (data not shown), with the false discovery rate value \>0.05. Thus, perform further analyses on these pathways from KEGG were not performed.

Additionally, the PPI network was constructed using STRING, and a total of 1,228 PPI pairs with a combined score of \>0.4 were selected. The map of the PPI network is presented in [Fig. 2](#f2-ol-0-0-8105){ref-type="fig"}. The number of nodes was 700, accounting for 99.30% of all target genes. The clustering coefficient of the PPI network was 0.626. RAN binding protein 2 (degree=40) had the highest degree of interactions in the PPI network. A sub-network of 172 PPI pairs (with degree \>15) was selected for further analyses ([Fig. 3](#f3-ol-0-0-8105){ref-type="fig"}).

### Supplementary information from TCGA database

In order to reveal the association between HOXA11-AS and NSCLC, a clinical study was performed using the raw data in TCGA. It was revealed that HOXA11-AS was upregulated in lung adenocarcinoma and squamous cell carcinoma compared with non-cancerous lung tissues (P\<0.0001; [Fig. 4A and B](#f4-ol-0-0-8105){ref-type="fig"}). The ROC curve revealed that the area under curve (AUC) of HOXA11-AS was 0.700 (95% confidence interval (CI), 0.636\~0.764; P=0.003) for patients with lung adenocarcinoma and 0.964 (95% CI, 0.946\~0.981; P\<0.0001) for patients with squamous cell carcinoma, which may gain a moderate or high diagnostic value of HOXA11-AS level in lung cancer ([Fig. 4C and D](#f4-ol-0-0-8105){ref-type="fig"}).

To elucidate the relationships between miR-642b and NSCLC, a clinical study was performed using the primary data in TCGA. It was revealed that miR-642b was significantly upregulated in lung adenocarcinoma (P=0.0001) and non-significantly upregulated in squamous cell carcinoma (P=0.348) compared with non-cancerous lung tissues ([Fig. 5A and B](#f5-ol-0-0-8105){ref-type="fig"}). The relationship between miR-642b and the prognosis of NSCLC was also investigated, and it was revealed that the high expression of miR-642b was associated with the overall survival of patients with adenocarcinoma (108.56±25.23 vs. 79.51±8.75; P=0.018; [Fig. 5C](#f5-ol-0-0-8105){ref-type="fig"}), which indicated that miR-642b may influence the prognosis of adenocarcinoma. The correlation between HOXA11-AS and miR-642b was also investigated, but no significant correlation was revealed in lung adenocarcinoma (r=−0.047, P=0.507; data not shown) and squamous cell carcinoma (r=0.123, P=0.148; data not shown) partly due to the fact that only 203 lung patients with adenocarcinoma and 140 patients with squamous cell carcinoma were included in the data from TCGA.

For target gene prediction, six target genes (ZNF350, HNRNPU, HMGB1, PDE4D, SYNCRIP and BHLHB9) of miR-642b-3p were identified by all four prediction algorithms. Then, further analyses were performed in order to determine whether the expressions of these genes were associated with NSCLC, based on the data from TCGA. It was revealed that the expressions of HNRNPU, SYNCRIP and BHLHB9 were upregulated in lung adenocarcinoma and squamous cell carcinoma, whereas PDE4D was significantly downregulated in lung adenocarcinoma and squamous cell carcinoma (P\<0.001). For the remaining two genes (ZNF350 and HMGB1), it was revealed that ZNF350 was upregulated in lung adenocarcinoma and significantly downregulated in lung squamous cell carcinoma (P\<0.0001), whereas HMGB1 was significantly downregulated in lung adenocarcinoma and significantly upregulated in lung squamous cell carcinoma (P\<0.05, [Figs. 6](#f6-ol-0-0-8105){ref-type="fig"} and [7](#f7-ol-0-0-8105){ref-type="fig"}). Subsequently, the relationship between these genes and overall survival or disease-free survival of NSCLC was investigated. It was revealed that in lung squamous cell carcinoma, ZNF350 and PDE4D were significantly associated with disease-free survival (P\<0.05). In lung adenocarcinoma, it was discovered that HNRNPU was associated with overall survival and disease-free survival (P\<0.05), and PDE4D and HMGB1 were related to disease-free survival (P\<0.05), and BHLHB9 was only associated with overall survival (P\<0.05, [Fig. 8](#f8-ol-0-0-8105){ref-type="fig"}). Additionally, the correlation between HOXA11-AS expression and the 6 target genes was analysed, and a weak negative correlation was revealed between HOXA11-AS and PDE4D or ZNF350 in lung adenocarcinoma and squamous cell carcinoma, whereas HNRNPU and SYNCRIP were positively correlated with HOXA11-AS. BHLHB9 and HMGB1 were revealed to have a weak positive correlation with HOX11-AS in lung adenocarcinoma, and a weak negative correlation with HOX11-AS in squamous cell carcinoma ([Table II](#tII-ol-0-0-8105){ref-type="table"}).

Amongst these results, PDE4D was downregulated in lung adenocarcinoma and squamous cell carcinoma, and a weak negative correlation was revealed between HOXA11-AS and PDE4D. Furthermore, the diagnostic value of PDE4D level in lung cancer was assessed and it was revealed that the AUC of PDE4D was 0.905 (95% CI, 0.879--0.931) for patients with lung adenocarcinoma and 0.665 (95% CI, 0.606--0.725) for patients with squamous cell carcinoma (P\<0.0001; [Fig. 9](#f9-ol-0-0-8105){ref-type="fig"}).

Discussion
==========

LncRNAs are non-protein-coding RNA molecules and the length of lncRNAs varies from 200 nucleotides to 100 kb ([@b20-ol-0-0-8105]). Numerous lncRNAs have been confirmed to have important functions in transcriptional regulation, epigenetic gene regulation or disease development ([@b13-ol-0-0-8105]--[@b15-ol-0-0-8105]). Additionally, lncRNAs have been associated with the tumorigenesis and progression of NSCLCs. To date, different lncRNAs have been reported to perform different functions in NSCLC, including lncRNA AK126698, GAS5-AS1 and TUSC7, which may be associated with cell proliferation, metastasis and a poor prognosis in NSCLC ([@b56-ol-0-0-8105]--[@b58-ol-0-0-8105]). Multiple previous reports have demonstrated that lncRNAs function in lung cancer by regulating the expression of miRNAs ([@b23-ol-0-0-8105]--[@b25-ol-0-0-8105],[@b59-ol-0-0-8105]). HOXA11-AS is a member of the homeobox family of genes. To the best of our knowledge, only two previous studies have reported the relationship between HOXA11-AS and cancer. Richards *et al* ([@b9-ol-0-0-8105]) conducted various functional experiments and analysed genome-wide data, and revealed that HOXA11-AS may inhibit the oncogenic phenotype of epithelial ovarian cancer, which may be enhanced by the T allele. Wang *et al* ([@b10-ol-0-0-8105]) used a high-throughput microarray and gene set enrichment analysis to demonstrate that HOXA11-AS may have a growth-promoting function in glioma via the regulation of cell cycle progression. However, the specific pathogenesis of HOXA11-AS in NSCLC remains unclear. Thus, the present study was designed using A549 cells to investigate the expression profile changes of miR-642b-3p following HOXA11-AS knockdown and the potential molecular mechanisms of HOXA11-AS in NSCLC.

In the present study, miR-642b-3p and its target genes (ZNF350, HNRNPU, HMGB1, PDE4D, SYNCRIP, BHLHB9) were analysed. To the best of our knowledge, only one previous study has reported on the relationship between miR-642b-3p and cancer. Hamam *et al* ([@b60-ol-0-0-8105]) revealed that miR-642b-3p was upregulated in breast cancer, and miR-642b-3p in combination with eight other upregulated miRNAs may be used for the early detection of breast cancer. Similarly, to this previous study, miR-642b-3p was upregulated in lung adenocarcinoma and squamous cell carcinoma, but the specific association between miR-642b-3p and NSCLC remains to be verified by functional experiments. Then, six target genes of miR-642b-3p were investigated and it was revealed that all six target genes were differentially expressed in lung adenocarcinoma and squamous cell carcinoma. Additionally, miR-642b-3p, ZNF350, HNRNPU, HMGB1, PDE4D and BHLHB9 were associated with the overall survival or disease-free survival of patients with lung adenocarcinoma or patients with squamous cell carcinoma based on TCGA database. Numerous previous studies have confirmed the association between these target genes and NSCLC. Deng *et al* ([@b61-ol-0-0-8105]) used a western blot analysis to determine that miR-193a-3p may inhibit the metastasis of lung cancer cells by de-regulating the expression of HNRNPU and other tumour-associated proteins. Numerous studies have assessed HMGB1. HMGB1 has been associated with cell migration, invasion, apoptosis, sensitivity to chemotherapy drugs and the prognosis of NSCLC ([@b62-ol-0-0-8105]--[@b64-ol-0-0-8105]). Karachaliou *et al* ([@b65-ol-0-0-8105]) revealed that PDE4D was associated with resistant epidermal growth factor receptor (EGFR)-mutant cancer cell lines, and the combination of EGFR tyrosine kinase inhibitors with PDE4D inhibitors may be an effective therapy for patients with EGFR-mutant NSCLC.

In the findings of the present study, PDE4D was downregulated in lung adenocarcinoma and squamous cell carcinoma, and a weak negative association was established between HOXA11-AS and PDE4D. Additionally, PDE4D was associated with disease-free survival of lung adenocarcinoma and squamous cell carcinoma, which indicated that PDE4D may influence the prognosis of adenocarcinoma. Therefore, the present study hypothesized that miR-642b-3p, which is regulated by lncRNA HOXA11-AS and targets PDE4D, may have a function in NSCLC tumorigenesis and deterioration.

Numerous studies have demonstrated that PDE4D may function in cancer via different pathways, including the EGFR/phosphoinositide 3-kinase/protein kinase B signalling pathway, MAPK pathway and Hedgehog pathway ([@b66-ol-0-0-8105]--[@b68-ol-0-0-8105]). However, further exploration is required to clarify the potential molecular mechanisms of PDE4D in NSCLC.

Additionally, there are limitations in the present study. The present study was conducted based on several online tools, including DAVID, STRING, Cytoscape and TCGA, which may only be used for reference. Furthermore, the specific molecular mechanisms of miR-642b-3p and genes it is associated with, require further elucidation through functional experiments. To assess this hypothesis, a series of experiments may be designed using various molecule, cell, tissue and animal models (including RT-qPCR, western blot analysis, proliferation, invasion and metastasis assays, dual luciferase reporter assay, RNA pull-down, chromatin immunoprecipitation, chicken embryo chorioallantoic membrane and nude mouse models). The present study, which focused on the function of the HOXA11-AS/miR-642b-3p/PDE4D axis, suggests a novel target for a clinical therapeutic strategy for NSCLC. In conclusion, HOXA11-AS may influence the expression of miR-642b-3p in the different biological processes of NSCLC by targeting the expression of PDE4D or other target genes. Raw data from TCGA confirmed the oncogenic function of miR-642b in lung adenocarcinoma and squamous cell carcinoma. The findings of the present study lay the foundation for future studies on the relationship between HOXA11-AS and the potential molecular mechanisms in NSCLC tumorigenesis and progression.

The present study was supported by the National Natural Science Foundation of China (grant nos. NSFC81560469 and NSFC81360327), the Scientific Research Project of Basic Ability Promoting for Middle Age and Youth Teachers of Guangxi Universities (grant no. KY2016YB077), the Natural Science Foundation of Guangxi, China (grant no. 2015GXNSFCA139009) and the Guangxi Provincial Health Bureau Scientific Research Project (grant nos. Z2013201 and Z2014055).

![A functional network of Gene Ontology terms for the target genes of microRNA-642b-3p in non-small cell lung cancer. The network for terms for (A) biological process, (B) cellular component (C) and molecular function.](ol-15-05-6147-g00){#f1-ol-0-0-8105}

![The protein-protein interaction network of differentially expressed genes.](ol-15-05-6147-g01){#f2-ol-0-0-8105}

![A sub-network of 172 protein-protein interaction pairs.](ol-15-05-6147-g02){#f3-ol-0-0-8105}

![Differential expression and ROC curve of HOXA11-AS in lung adenocarcinoma and squamous cell carcinoma based on The Cancer Genome Atlas database. The differential expression of HOXA11-AS in (A) lung adenocarcinoma and (B) squamous cell carcinoma. The ROC curve of HOXA11-AS in (C) lung adenocarcinoma and (D) squamous cell carcinoma. ROC, receiving operator characteristic; HOXA11-AS, HOXA11 antisense RNA.](ol-15-05-6147-g03){#f4-ol-0-0-8105}

![Differential expression of miR-642b in lung adenocarcinoma and squamous cell carcinoma based on the Cancer Genome Atlas database. The expression of miR-642b between normal lung and (A) lung adenocarcinoma cells or (B) lung squamous cell carcinoma cells. (C) Kaplan-Meier curves for miR-642b expression in lung adenocarcinoma. miR, microRNA.](ol-15-05-6147-g04){#f5-ol-0-0-8105}

![Differential expression of ZNF350, HNRNPU, HMGB1, PDE4D, SYNCRIP, and BHLHB9 between lung adenocarcinoma and normal lung tissues based on the Cancer Genome Atlas database. Differential expression of (A) ZNF350, (B) HNRNPU, (C) HMGB1, (D) PDE4D, (E) SYNCRIP and (F) BHLHB9. ZNF350, zinc finger protein 350; HNRNPU, heterogeneous nuclear ribonucleoprotein U; HMGB1, high mobility group box 1; PDE4D, phosphodiesterase 4D; SYNCRIP, synaptotagmin binding cytoplasmic RNA interacting protein; BHLHB9, basic helix-loop-helix family member B9.](ol-15-05-6147-g05){#f6-ol-0-0-8105}

![Differential expression of ZNF350, HNRNPU, HMGB1, PDE4D, SYNCRIP and BHLHB9 between lung squamous cell carcinoma and normal lung tissues based on the Cancer Genome Atlas database. Differential expression of (A) ZNF350, (B) HNRNPU, (C) HMGB1, (D) PDE4D, (E) SYNCRIP and (F) BHLHB9. ZNF350, zinc finger protein 350; HNRNPU, heterogeneous nuclear ribonucleoprotein U; HMGB1, high mobility group box 1; PDE4D, phosphodiesterase 4D; SYNCRIP, synaptotagmin binding cytoplasmic RNA interacting protein; BHLHB9, basic helix-loop-helix family member B9.](ol-15-05-6147-g06){#f7-ol-0-0-8105}

![Kaplan-Meier curves for ZNF350, HNRNPU, HMGB1, PDE4D and BHLHB9 expression in lung adenocarcinoma and squamous cell carcinoma based on The Cancer Genome Atlas database. (A) Disease-free survival of patients with different ZNF350 expression levels in lung squamous cell carcinoma. Patients with high ZNF350 expression had a significantly poorer prognosis (85.14±7.98) compared with those with low expression (105.02±5.76) (P=0.039). (B) Disease-free survival of patients with differing PDE4D expression levels in lung squamous cell carcinoma. Patients with high PDE4D expression had a significantly poorer prognosis (83.15±8.29) than those with low expression (105.61±6.14) (P=0.012). (C) Disease-free survival of patients with different PDE4D expression levels in lung adenocarcinoma. Patients with low PDE4D expression had a significantly poorer prognosis (153.38±12.61) than those with high expression (112.77±14.03) (P=0.046). (D) Overall survival of patients with different HNRNPU expression levels in lung adenocarcinoma. Patients with high HNRNPU expression had a significantly poorer prognosis (70.68±9.93) than those with low expression (102.72±11.13) (P=0.029). (E) Disease-free survival of patients with different HNRNPU expression levels in lung adenocarcinoma. Patients with high HNRNPU expression had a significantly poorer prognosis (101.69±17.09) than those with low expression (142.28±14.76) (P=0.002). (F) Disease-free survival of patients with different HMGB1 expression levels in lung adenocarcinoma. Patients with high HMGB1 expression had a significantly poorer prognosis (92.53±14.88) than those with low expression (150.23±15.44) (P=0.009). (G) Overall survival of patients with different BHLHB9 expression levels in lung adenocarcinoma. Patients with low BHLHB9 expression had a significantly poorer prognosis (109.70±14.43) than those with high expression (71.41±7.96) (P=0.047). ZNF350, zinc finger protein 350; HNRNPU, heterogeneous nuclear ribonucleoprotein U; HMGB1, high mobility group box 1; PDE4D, phosphodiesterase 4D; SYNCRIP, synaptotagmin binding cytoplasmic RNA interacting protein; BHLHB9, basic helix-loop-helix family member B9.](ol-15-05-6147-g07){#f8-ol-0-0-8105}

![ROC curve for PDE4D in lung adenocarcinoma and squamous cell carcinoma based on The Cancer Genome Atlas database. (A) ROC curve for PDE4D in lung adenocarcinoma. (B) ROC curve for PDE4D in squamous cell carcinoma. ROC, receiving operator characteristic; PDE4D, phosphodiesterase 4D.](ol-15-05-6147-g08){#f9-ol-0-0-8105}

###### 

The top 5 GO functional annotation for the target genes of miR-642b-3p.

  A, Biological processes                                                                                   
  ---------------------------- ------------------------------------------ ---------------------- ---------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO.0007275                   Multicellular organism development         184                    0.000122   ABCA12, ABI1, ADAR, ADRBK1, AGPAT5, AHR, AK4, AMBN, ANKRD1, ANKRD17, ARL6, ASB2, ATP8B1, ATXN3, BBS4, BCL11B, BCOR, BHLHB9, BMP3, CACNA1G, CALM1, CAMSAP1, CASQ1, CCK, CCNA2, CD109, CDH22, CDK5R2, CDKN1A
  GO.0048731                   System development                         165                    0.000122   ABCA12, ABI1, ADAR, ADRBK1, AGPAT5, AHR, AK4, AMBN, AMHR2, ANKRD1, ANKRD17, ARL6, ASB2, ATP8B1, ATXN3, BBS4, BCL11B, BCOR, BHLHB9, BMP3, CACNA1G, CALM1, CAMSAP1, CASQ1, CCK, CCNA2, CD109, CDH22, CDK5R2, CDKN1A
  GO.0008152                   Metabolic process                          353                    0.000356   ABCA12, ABHD10, ABHD2, ABI1, ABRA, ADAM22, ADAR, ADORA2B, ADRBK1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, AMHR2, ANGPT1, ANKRD1, ARSD, ASB2, ASCL1, ATAD1, ATG10, ATG12, ATP9A, B4GALT4, BAZ1A, BBS4, BCL11B, BCLAF1, BCOR
  GO.0009893                   Positive regulation of metabolic process   159                    0.000356   ABI1, ACAP2, ADAR, ADRBK1, AFF1, ANKRD1, ANKRD6, APP, ARHGAP18, ARHGAP31, ARHGAP6, ARHGEF37, ASB2, ASCL1, ATAD1, ATG10, ATXN3, BCLAF1, CALM1, CAND2, CARD8, CASP10, CCK, CCNA2, CCPG1, CDC25B, CDK5R2, CDKN1A, CENPE, CHRNA7
  GO.0042325                   Regulation of phosphorylation                75                   0.000356   ABI1, ADAR, ADORA2B, ANKRD6, APP, BMP3, CALM1, CCK, CCNA2, CD109, CDC25B, CDKN1A, CENPE, CHRNA7, CISH, CREBL2, DNAJC27, EIF2AK2, EPGN, EPHA7, EPHB1, FAM129A, FZD1, FZD4, GAB1, GDF6, GMFB, GRM1, HIPK3, IBTK
                                                                                                            
  **B, Cellular components**                                                                                
                                                                                                            
  **GO ID**                    **GO term**                                **Count in network**   **FDR**    **Gene symbol (top 30 genes)**
                                                                                                            
  GO.0005622                   Intracellular                              470                    3.88E-05   ABCA12, ABHD10, ABI1, ABRA, ACAP2, ADAR, ADORA2B, ADRBK1, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, ANKRD1, ANKRD17, ANKRD6, ANKS1B, ANO5, ANTXR2, APP, ARHGAP18, ARHGAP31, ARHGAP6, ARHGEF37, ARSD, ASB2, ASCL1, ASTN2, ATG10
  GO.0043227                   Membrane-bound organelle                   423                    0.000126   ABCA12, ABHD10, ABI1, ACAP2, ADAR, AFF1, AFF4, AGPAT5, AHR, AK4, AKAP4, ALDH4A1, AMOTL2, ANGPT1, ANKRD1, ANKRD17, ANKRD6, ANKS1B, ANO5, ANTXR2, AP1S3, APP, ARL6, ARSD, ASCL1, ASTN2, ATG12, ATP8B1, ATP9A, ATXN3
  GO.0044424                   Intracellular part                         455                    0.000126   ABCA12, ABHD10, ABI1, ABRA, ACAP2, ADAR, ADRBK1, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, ANKRD1, ANKRD17, ANKRD6, ANKS1B, ANO5, ANTXR2, APP, ARHGAP18, ARHGAP31, ARHGAP6, ARHGEF37, ARSD, ASB2, ASCL1, ASTN2, ATG10
  GO.0043226                   Organelle                                  439                    0.00018    ABCA12, ABHD10, ABI1, ABRA, ACAP2, ADAR, ADRBK1, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, AMOTL2, ANGPT1, ANKRD1, ANKRD17, ANKRD6, ANKS1B, ANTXR2, AP1S3, APP, ARHGAP6, ARL6, ARSD, ASCL1, ASTN2, ATG12, ATP8B1, ATP9A
  GO.0043229                   Intracellular organelle                    411                    0.000197   ABCA12, ABHD10, ABI1, ABRA, A CAP2, ADAR, AFF1, AFF4, AGPAT5, AHR, AK4, ALDH4A1, AMOTL2, ANKRD1, ANKRD17, ANKRD6, ANKS1B, ANO5, ANTXR2, AP1S3, APP, ARHGAP6, ARL6, ARSD, ASCL1, ASTN2, ATP8B1, ATP9A, ATXN3, B3GALT1
                                                                                                            
  **C, Molecular functions**                                                                                
                                                                                                            
  **GO ID**                    **GO term**                                **Count in network**   **FDR**    **Gene symbol (top 30 genes)**
                                                                                                            
  GO.0005488                   Binding                                    392                    0.00069    ABCA12, ABI1, ABRA, ACAP2, ADAR, ADRBK1, AHR, AK4, AKAP4, ALDH4A1, AMBN, AMHR2, ANGPT1, ANKMY1, ANKRD1, ANKRD17, ANKS1B, ANTXR2, APP, ARHGAP6, ARL6, ARSB, ARSD, ATAD1, ATP8B1, ATP9A, ATXN3, B4GALT4, BAIAP3, BAZ1A
  GO.0003674                   Molecular function                         456                    0.000857   ABCA12, ABHD10, ABHD2, ACAP2, ADAR, ADORA2B, ADRBK1, AFF1, AFF4, AGPAT5, AHR, AK4, AKAP4, ALDH4A1, AMBN, ANGPT1, ANKMY1, ANKRD1, ANKRD17, ANKS1B, ANO5, ANTXR2, AP1S3, APP, ARHGAP18, ARHGAP31, ARHGAP6, ARHGEF37, ARL6, ARSB
  GO.0005515                   Protein binding                            200                    0.000857   ABCA12, ABI1, ABRA, ADAM22, ADAMTS8, ADRBK1, AHR, AKAP4, ALDH4A1, AMBN, ANGPT1, ANKRD1, ANKS1B, APP, ARHGAP6, ASCL1, ATXN3, BAIAP3, BAZ2A, BBS4, BCOR, BHLHB9, BICD2, BMP3, C18orf42, CACNA1B, CACNA1G, CALM1, CAMSAP1, CARD8
  GO.0004705                   JUN kinase activity                          3                    0.0274     MAPK10, MAPK8, MAPK9
  GO.0061578                   Lys63-specific deubiquitinase activity       3                    0.0274     ATXN3, CYLD, YOD1

GO, Gene Ontology; FDR, false discovery rate.

###### 

Correlations between HOXA11 antisense RNA expression and the six target genes in lung adenocarcinoma and squamous cell carcinoma based on The Cancer Genome Atlas via Spearman\'s test.

                                      Gene name                                             
  ------------------------- --------- ----------- ---------- ---------- -------- ---------- --------
  Lung adenocarcinoma       R-value   −0.004      0.307      0.286      −0.124   0.303      0.128
                            P-value   0.949       \<0.0001   \<0.0001   0.049    \<0.0001   0.041
  Squamous cell carcinoma   R-value   −0.067      0.200      −0.055     −0.068   0.187      −0.093
                            P-value   0.639       0.160      0.704      0.637    0.188      0.517

[^1]: Contributed equally
